| Name | Title | Contact Details |
|---|
QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms.
Engage Therapeutics was founded by Greg Mayes, President and CEO; and Jouko Isojarvi MD, PhD Executive Vice President and Chief Medical Officer. Engage`s founders bring a combination of strong biopharma pedigrees and personal, family connections to epilepsy. Greg’s son has epilepsy, while Jouko has spent his entire career taking care of epilepsy patients as well as developing and commercializing approved treatments for this condition.
What unites us at Rentschler Biopharma, is the passion for what we do. As a full-service CDMO we are your outsourcing partner for the bioprocess development, cGMP manufacturing and aseptic filling of biopharmaceuticals as well as for the elaboration of approval strategies for your products. Thanks to our many years of experience, the quality of our associated consulting activities, and our expertise in finding solutions, we are among the top suppliers in our field. Founded in 1927, Rentschler is a family owned and independent company. Our company structure guarantees rapid decision-making and efficient, smooth-running processes, and consequently keeping project timelines. Already in the early beginnings of biotechnology, Rentschler has built up a reputation with the development of different Interferon products (Fiblaferon, Polyferon). Nowadays, our attention is firmly focused on your products. For the success of your project we can refer to our experience in various molecules like antibodies, fusion proteins or enzymes. Thanks to our focus on innovations, we are always on the cutting edge of technologies.
Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better expects to go public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the summer of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies.
Endocyte Inc is a West Lafayette, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.